Stratec's prosthetics sales hit by strategy change:
This article was originally published in Clinica
Sales in Stratec's prosthetics business were SwFr50 million ($34 million) in 1998, compared with SwFr59 million in the previous year. The drop in sales resulted from the company's strategy to manufacture and market its own prosthetic products. Oberdorf-based Stratec says the business grew 8% in the second half, partly making up for the 27% drop in the first half. However, sales in Stratec's core business, osteosynthesis, were SwFr215 million in 1998, up 7% on the previous year, above the market rate. The spinal business performed particularly well, the company says. Total sales were SwFr265 million, up 2% on the previous year.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.